Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1974809 | 0.92 | EGFR (0.44) | EGFRTSHRL3MBTL1TDP1CNR2 | |
| SCHEMBL1976187 | 0.89 | ESR1 (0.39) | EGFRTSHRL3MBTL1TDP1ADORA3 | |
| SCHEMBL1974320 | 0.87 | MAPT (0.44) | TSHRL3MBTL1TDP1GAAADORA3 | |
| SCHEMBL1974246 | 0.87 | CDC7 (0.39) | TSHRL3MBTL1TDP1MAPK1ADORA1 | |
| SCHEMBL1972792 | 0.85 | ADORA2A (0.42) | EGFRTSHRL3MBTL1TDP1MAPK1 | |
| SCHEMBL1975712 | 0.85 | ESR1 (0.43) | TSHRL3MBTL1TDP1MAPK1CYP3A4 | |
| SCHEMBL1975927 | 0.84 | ADORA2A (0.41) | TSHRL3MBTL1TDP1MAPK1ALDH1A1 | |
| SCHEMBL1974100 | 0.84 | ESR1 (0.43) | TSHRL3MBTL1TDP1MAPK1ALDH1A1 | |
| SCHEMBL1973059 | 0.83 | ESR1 (0.44) | TSHRL3MBTL1TDP1MAPK1CYP3A4 | |
| SCHEMBL1974203 | 0.83 | L3MBTL1 (0.45) | TSHRL3MBTL1TDP1GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000006-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8703795-B2 | Thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-1866318-B1 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN INC (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-1866318-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006094292-A2 | THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | FIBROGEN, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | FIBROGEN, INC. | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221422-A1 | NOVEL THIENOPYRIDINE COMPOUNDS, AND METHODS OF USE THEREOF | HIF1AN, HIF1A, EGLN2 | EGFR 4595/4885TSHR 2835/4885L3MBTL1 3104/4885 |
| US-20060199836-A1 | Novel thienopyridine compounds, and methods of use thereof | HIF1AN, HIF1A, EGLN2 | EGFR 4595/4885TSHR 2835/4885L3MBTL1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.